- Home
- SLAB vs ACAD Comparison
SLAB vs ACAD Comparison
Compare SLAB & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLAB
- ACAD
- Stock Information
- Founded
- SLAB 1996
- ACAD 1993
- Country
- SLAB United States
- ACAD United States
- Employees
- SLAB N/A
- ACAD N/A
- Industry
- SLAB Semiconductors
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- SLAB Technology
- ACAD Health Care
- Exchange
- SLAB Nasdaq
- ACAD Nasdaq
- Market Cap
- SLAB 4.7B
- ACAD 3.8B
- IPO Year
- SLAB 2000
- ACAD 2004
- Fundamental
- Price
- SLAB $126.36
- ACAD $21.87
- Analyst Decision
- SLAB Buy
- ACAD Buy
- Analyst Count
- SLAB 11
- ACAD 21
- Target Price
- SLAB $144.00
- ACAD $29.43
- AVG Volume (30 Days)
- SLAB 240.1K
- ACAD 1.9M
- Earning Date
- SLAB 11-04-2025
- ACAD 11-05-2025
- Dividend Yield
- SLAB N/A
- ACAD N/A
- EPS Growth
- SLAB N/A
- ACAD 615.00
- EPS
- SLAB N/A
- ACAD 1.33
- Revenue
- SLAB $742,807,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- SLAB $37.60
- ACAD $14.01
- Revenue Next Year
- SLAB $19.26
- ACAD $12.00
- P/E Ratio
- SLAB N/A
- ACAD $16.47
- Revenue Growth
- SLAB 47.10
- ACAD 14.41
- 52 Week Low
- SLAB $82.82
- ACAD $13.40
- 52 Week High
- SLAB $160.00
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- SLAB 38.89
- ACAD 47.45
- Support Level
- SLAB $129.50
- ACAD $22.05
- Resistance Level
- SLAB $140.25
- ACAD $22.90
- Average True Range (ATR)
- SLAB 4.54
- ACAD 0.75
- MACD
- SLAB -0.80
- ACAD 0.18
- Stochastic Oscillator
- SLAB 31.36
- ACAD 55.62
About SLAB Silicon Laboratories Inc.
Silicon Laboratories Inc Inc is a provider of secure, intelligent wireless technology for a more connected world. The company's integrated hardware and software platform, intuitive development tools, industry ecosystem, and robust support help customers build industrial, commercial, home, and life applications. Company make it easy for developers to solve complex wireless challenges throughout the product lifecycle and get to market quickly with solutions that transform industries, grow economies, and improve lives. Company operates in USA, China, Taiwan and Rest of World, with maximum revenue from rest of the world.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.